Heterogeneity could be attributed to methodological differences in study design, therapeutic regimens (anti-CTLA-4, anti-PD-1/PD-L1, or combination therapy), and tumor microenvironment characteristics across tumor types. This evidence concerns the gene PDCD1 and neoplasm.